Abstract

Tissue engineered scaffolds and matrices have been investigated over the past decade for their potential in spinal cord repair. They provide a 3-D substrate that can be permissive for nerve regeneration yet have other roles including neuroprotection, altering the inflammatory cascade and mechanically stabilizing spinal cord tissue after injury. In this study we investigated very small lesions (approx. 0.25 μL in volume) of the dorsal column into which a phase-separated poly(2-hydroxyethyl methacrylate) hydrogel scaffold is implanted. Using fluorescent immunohistochemistry to quantify glial scarring, the poly(2-hydroxyethyl methacrylate) scaffold group showed reduced intensity compared to lesion controls for GFAP and the chondroitin sulfate proteoglycan neurocan after 6 days. However, the scaffold and tissue was also pushed dorsally after 6 days while the scaffold was not integrated into the spinal cord after 28 days. Overall, this small-lesion spinal cord injury model provided information on the host tissue reaction of a TE scaffold while reducing animal discomfort and care.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.